BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Han C, Wang SM, Bahk WM, Lee SJ, Patkar AA, Masand PS, Mandelli L, Pae CU, Serretti A. A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial. Clin Psychopharmacol Neurosci 2018;16:469-80. [PMID: 30466219 DOI: 10.9758/cpn.2018.16.4.469] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Lee KH, Park GY, Bahk WM, Lee SJ, Pae CU. The Usefulness and Clinical Characteristics of Antidepressant Use for Stroke Patients with Rehabilitation Program: An Exploratory Analysis. Clin Psychopharmacol Neurosci 2020;18:445-9. [PMID: 32702223 DOI: 10.9758/cpn.2020.18.3.445] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Ruaño G, Holford T, Seip RL, Goethe JW, Mehendru R. Pharmacogenetic clinical decision support for psychiatric hospitalization: Design of the CYP-GUIDES randomized controlled trial. Contemporary Clinical Trials 2019;83:27-36. [DOI: 10.1016/j.cct.2019.06.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
3 Lee KH, Bahk WM, Lee SJ, Serretti A, Pae CU. A Practical Utility and Benefit of Pharmacogenetic-based Antidepressant Treatment Strategy for Major Depressive Disorder Patients with Difficult-to-treat. Clin Psychopharmacol Neurosci 2021;19:160-5. [PMID: 33508800 DOI: 10.9758/cpn.2021.19.1.160] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Lee KH, Bahk WM, Lee SJ, Pae CU. Effectiveness and Tolerability of Korean Red Ginseng Augmentation in Major Depressive Disorder Patients with Difficult-to-treat in Routine Practice. Clin Psychopharmacol Neurosci 2020;18:621-6. [PMID: 33124595 DOI: 10.9758/cpn.2020.18.4.621] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Stäuble CK, Lampert ML, Allemann S, Hatzinger M, Hersberger KE, Meyer Zu Schwabedissen HE, Imboden C, Mikoteit T. Pharmacist-guided pre-emptive pharmacogenetic testing in antidepressant therapy (PrePGx): study protocol for an open-label, randomized controlled trial. Trials 2021;22:919. [PMID: 34906208 DOI: 10.1186/s13063-021-05724-5] [Reference Citation Analysis]
6 Anmella G, Vilches S, Espadaler-Mazo J, Murru A, Pacchiarotti I, Tuson M, Garriga M, Solé E, Brat M, Fico G, Vieta E. Genetic Variations Associated with Long-Term Treatment Response in Bipolar Depression. Genes (Basel) 2021;12:1259. [PMID: 34440433 DOI: 10.3390/genes12081259] [Reference Citation Analysis]
7 Aboelbaha S, Zolezzi M, Elewa H. Effect of Pharmacogenetic-Based Decision Support Tools in Improving Depression Outcomes: A Systematic Review. Neuropsychiatr Dis Treat 2021;17:2397-419. [PMID: 34321882 DOI: 10.2147/NDT.S312966] [Reference Citation Analysis]
8 Han C, Wang SM, Bahk WM, Lee SJ, Patkar AA, Masand PS, Pae CU. The Potential Utility of Aripiprazole Augmentation for Major Depressive Disorder with Mixed Features Specifier: A Retrospective Study. Clin Psychopharmacol Neurosci 2019;17:495-502. [PMID: 31671486 DOI: 10.9758/cpn.2019.17.4.495] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
9 Laplace B, Calvet B, Lacroix A, Mouchabac S, Picard N, Girard M, Charles E. Acceptability of Pharmacogenetic Testing among French Psychiatrists, a National Survey. J Pers Med 2021;11:446. [PMID: 34064030 DOI: 10.3390/jpm11060446] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
10 Vilches S, Tuson M, Vieta E, Álvarez E, Espadaler J. Effectiveness of a Pharmacogenetic Tool at Improving Treatment Efficacy in Major Depressive Disorder: A Meta-Analysis of Three Clinical Studies. Pharmaceutics 2019;11:E453. [PMID: 31480800 DOI: 10.3390/pharmaceutics11090453] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
11 Severe J, Greden JF, Reddy P. Consequences of Recurrence of Major Depressive Disorder: Is Stopping Effective Antidepressant Medications Ever Safe? Focus (Am Psychiatr Publ) 2020;18:120-8. [PMID: 33162849 DOI: 10.1176/appi.focus.20200008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Kim JM, Stewart R, Kang HJ, Kim JW, Lee HJ, Jhon M, Lee JY, Kim SW, Shin IS. Predictors of relapse following a stepwise psychopharmacotherapy regime in patients with depressive disorders. J Affect Disord 2021;293:109-16. [PMID: 34175592 DOI: 10.1016/j.jad.2021.06.015] [Reference Citation Analysis]
13 Eugene AR. Optimizing drug selection in psychopharmacology based on 40 significant CYP2C19- and CYP2D6-biased adverse drug reactions of selective serotonin reuptake inhibitors. PeerJ 2019;7:e7860. [PMID: 31616600 DOI: 10.7717/peerj.7860] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]